TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04492020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Description: For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Description: For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
Study: NCT05084703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional tests
Description: * Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~* Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional tests
Description: * Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~* Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test
Study: NCT02438852

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride
Description: Given IV
Study: NCT00759135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg NX-1207
Description: Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.125 mg NX-1207
Description: Low dose; single intraprostatic injection of 0.125 mg NX-1207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: finasteride
Description: Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
Study: NCT04000763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: superficial peroneal nerve stimulation
Description: A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.
Study: NCT03994276

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chickpea powder
Description: Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea powder
Description: Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
Study: NCT00859807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavoquine®, Camoquin® Suspension
Description: Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
Study: NCT00403013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning and anesthesia
Description: Positioning during axillary plexus block
Study: NCT00993304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
Study: NCT00403013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positioning and anesthesia
Description: Positioning during axillary plexus block
Study: NCT04621994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Steri Strips
Description: Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
Study: NCT00628498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Study: NCT04646577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
Study: NCT00993304

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
Study: NCT04646577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS
Description: Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS
Description: Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
Study: NCT03595735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenflow Spring System
Description: The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
Study: NCT01823380

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: Blood test
Study: NCT02235792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
Study: NCT00726128

Intervention type: DEVICE
Intervention: VueLock™ Anterior Cervical Plate
Description: Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
Study: NCT01840488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irosustat (BN83495)
Description: Three parts (A, B \& C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression.
Study: NCT03402932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory amplified
Description: The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory amplified
Description: The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual
Description: The cognitive test will be administered visually by using timed computer slides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual
Description: The cognitive test will be administered visually by using timed computer slides.
Study: NCT01758432

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Apixaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Apixaban
Study: NCT03402932

Intervention type: OTHER
Group type: OTHER
Intervention: Visual
Description: The cognitive test will be administered visually by using timed computer slides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory unamplified
Description: The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory unamplified
Description: The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
Study: NCT04406389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium
Description: Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondapariniux
Description: Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondapariniux
Description: Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol
Study: NCT00145912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI + CATCH-IT Internet Site
Description: MI + CATCH-IT Internet Site

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BA (brief advice) + CATCH-IT Internet site
Description: BA (brief advice) + CATCH-IT Internet site
Study: NCT02070874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telehealth enhanced pain management
Study: NCT02931903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita Enamic (hybrid dental ceramic)
Description: Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lithium disilicate glass-ceramic
Description: All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
Study: NCT01464034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
Study: NCT00675753

Intervention type: GENETIC
Intervention: Blood spot specimens will be drawn
Description: Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping

Intervention type: GENETIC
Intervention: Blood spot specimens will be drawn
Description: Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
Study: NCT01983709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells
Description: This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10\^6 cells/kg or a maximum dose of 1 x 10\^8 total cells IV 4 days prior to undergoing a planned prostatectomy.~The remaining subjects will receive a single dose of 2 x 10\^6 cells/kg or a maximum dose of 2 x 10\^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy.
Study: NCT02570516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
Study: NCT04049617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evixapodlin
Description: Tablets administered orally.
Study: NCT03293784

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
Description: Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
Description: Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks.
Study: NCT03908177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic Dental Implant
Description: The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Dental Implant
Description: The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
Study: NCT02512926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study: NCT03567382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent HBV vaccine
Description: Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent HBV vaccine
Description: Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
Study: NCT03853018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CWAT intervention
Description: Participant in the intervention group will wear an activity tracker for 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CWAT intervention
Description: Participant in the intervention group will wear an activity tracker for 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CWAT + motivation intervention group
Description: Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
Study: NCT03236415

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Drug Eluting Stent
Description: Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB Bioresorbable Vascular Scaffold
Description: Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
Study: NCT00856219

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Continuous
Description: Continuous Tube Feeding for 72 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Intermittent
Description: Intermittent Tube Feedings

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Continuous
Description: Parenteral Continuously for 72 hours
Study: NCT03712982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention to Variability - Patient Only
Description: In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention to Variability - Partner Only
Description: In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology in their partner that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention to Variability - Patient & Partner
Description: Same as patient and partner only conditions, just that in this condition both the patient and partner do their corresponding intervention rather than only one of them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infertility Stories - Reading
Description: Reading Stories About Others' Infertility Experiences
Study: NCT01517659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq CoolSculpting System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT01825889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib